Evotec (EVO) Stock Price, News & Analysis

Company Overview

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design. Its proprietary technologies and automation solutions are engineered to streamline early-stage research, reduce timelines and costs, and improve the probability of success for small molecules, biologics, and cell therapies.

Founded in 1993, Evotec has expanded its capabilities through strategic collaborations, acquisitions, and the growth of its global R&D infrastructure. The company maintains research sites across Europe, North America, and Asia, providing clients with access to diverse scientific expertise and regional innovation hubs in major life sciences clusters.

Evotec’s leadership team brings together seasoned executives from the biotechnology and pharmaceutical industries, guiding a strategic focus on both fee-for-service engagements and milestone-based alliances. Under this direction, Evotec continues to evolve as an integrated drug discovery powerhouse, advancing its own proprietary pipeline alongside its partnership-driven business model.

Key Stats

• Today's Range: $3.40 to $3.49
• 50-Day Range: $3.49 to $4.34
• 52-Week Range: $2.84 to $5.64
• Volume: 39,644 shs
• Average Volume: 94,064 shs
• Market Capitalization: $1.21 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.40
• Consensus Rating: Moderate Buy

Evotec Stock Analysis - MarketRank™

Evotec scored higher than 38% of companies evaluated by MarketBeat, and ranked 738th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Evotec has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Evotec has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Evotec are expected to grow in the coming year, from ($0.41) to ($0.18) per share.

Price to Book Value per Share Ratio

Evotec has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.20% of the float of Evotec has been sold short.

Short Interest Ratio / Days to Cover

Evotec has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in Evotec has recently increased by 3.79%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evotec does not currently pay a dividend.

Dividend Growth

Evotec does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.20% of the float of Evotec has been sold short.

Short Interest Ratio / Days to Cover

Evotec has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in Evotec has recently increased by 3.79%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: N/A

News Sentiment

Evotec has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.12 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Evotec this week, compared to 3 articles on an average week.

MarketBeat Follows

3 people have added Evotec to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evotec insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 5.81% of the stock of Evotec is held by institutions.

EVO Stock Analysis - Frequently Asked Questions

How have EVO shares performed this year?

Evotec's stock was trading at $4.16 at the start of the year. Since then, EVO stock has decreased by 18.3% and is now trading at $3.40.

When did Evotec IPO?

Evotec (EVO) raised $435 million in an IPO on Thursday, November 4th 2021. The company issued 20,000,000 shares at $21.75 per share.

Who are Evotec's major shareholders?

Evotec's top institutional shareholders include DCF Advisers LLC (0.31%), WCM Investment Management LLC (0.08%), Pitcairn Co. (0.07%) and Envestnet Asset Management Inc. (0.03%).

How do I buy shares of Evotec?

Shares of EVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Evotec own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evotec investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), American Water Works (AWK) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Today: 9/02/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EVO
• CIK: 1412558
• Web: www.evotec.com
• Phone: 49-40-560-81-0
• Fax: 49-40-5608-1222
• Employees: 4,827
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Evotec: $5.40
• High Price Target: $7.00
• Low Price Target: $3.80
• Potential Upside/Downside: +54.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$212.18 million
• Net Margins: -20.14%
• Pretax Margin: -17.65%
• Return on Equity: -16.94%
• Return on Assets: -8.14%

Debt

• Debt-to-Equity Ratio: 0.42
• Current Ratio: 1.58
• Quick Ratio: 1.49

Sales & Book Value

• Annual Sales: $862.40 million
• Price / Sales: 1.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.91 per share
• Price / Book: 1.20

Miscellaneous

• Outstanding Shares: 355,110,000
• Free Float: N/A
• Market Cap: $1.24 billion
• Optionable: Not Optionable
• Beta: 1.72